{"id":9486,"date":"2012-07-11T00:00:00","date_gmt":"2012-07-10T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2012\/07\/11\/grifols-adquireix-el-40-del-capital-de-la-biotecnologica-vcn-biosciences\/"},"modified":"2022-06-13T12:15:11","modified_gmt":"2022-06-13T10:15:11","slug":"grifols-adquireix-el-40-del-capital-de-la-biotecnologica-vcn-biosciences","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2012\/07\/grifols-adquireix-el-40-del-capital-de-la-biotecnologica-vcn-biosciences\/","title":{"rendered":"Grifols adquireix el 40% del capital de la biotecnol\u00f2gica VCN Biosciences"},"content":{"rendered":"<p>L\u2019empresa farmac\u00e8utica multinacional <a href=\"http:\/\/www.grifols.com\">Grifols<\/a>, a trav\u00e9s de la filial Gri-Cel, ha adquirit el 40% del capital de la companyia biotecnol\u00f2gica catalana <a href=\"http:\/\/www.vcnbiosciences.com\/\">VCN Biosciences<\/a>, dedicada a la recerca i el desenvolupament de nous agents per tractar el c\u00e0ncer basats en adenovirus oncol\u00edtics. VCN va ser fundada l\u2019any 2009 per tres investigadors de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) i l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL): Manel Cascall\u00f3, Ramon Alemany i Gabriel Capell\u00e1.<\/p>\n<p>El projecte m\u00e9s avan\u00e7at de VCN s\u2019orienta al tractament del c\u00e0ncer de p\u00e0ncrees amb virus. L&#8217;entrada de Grifols en el capital de VCN permetr\u00e0 seguir endavant amb el desenvolupament d&#8217;aquesta nova aproximaci\u00f3 terap\u00e8utica, que actualment s\u2019est\u00e0 provant en fase precl\u00ednica. L\u2019estudi cl\u00ednic amb pacients est\u00e0 previst per al 2013. Des de 2011 aquest agent terap\u00e8utic \u00e9s considerat un \u201cmedicament orfe\u201d per l&#8217;Ag\u00e8ncia Europea del Medicament (EMA). A Europa hi ha unes 60.000 persones afectades per c\u00e0ncer de p\u00e0ncrees.<\/p>\n<p>Grifols \u00e9s la tercera companyia del m\u00f3n en la producci\u00f3 de f\u00e0rmacs biol\u00f2gics derivats del plasma. L\u2019empresa tamb\u00e9 investiga i desenvolupa ter\u00e0pies avan\u00e7ades per tractar diverses malalties. En aquest sentit, l\u2019entrada de Grifols a VCN s\u2019emmarca en l\u2019estrat\u00e8gia de la companyia per promoure noves tecnologies per donar resposta a necessitats m\u00e8diques, en aquest cas, el c\u00e0ncer de p\u00e0ncrees.<\/p>\n<p>Despr\u00e9s de l\u2019adquisici\u00f3 del 40% de VCN, Grifols s\u2019ha comprom\u00e8s a ampliar la inversi\u00f3 en un futur si s\u2019aconsegueixen obtenir els resultats esperats. VCN Biosciences t\u00e9 previst traslladar les seves oficines a les instal\u00b7lacions corporatives de Grifols situades a Sant Cugat del Vall\u00e8s. Actualment est\u00e0 instal\u00b7lada a l\u2019espai Biopol\u2019H de l&#8217;Hospitalet de Llobregat.<\/p>\n<p>L&#8217;entrada de Grifols en l&#8217;accionariat de VCN Biosciences garanteix la viabilitat dels seus projectes en marxa, cosa que permetr\u00e0 continuar amb el desenvolupament de nous tractaments viroterap\u00e8utics contra el c\u00e0ncer.<\/p>\n<p><strong>Viroter\u00e0pia<\/strong> <strong><br \/>\n<\/strong> La viroter\u00e0pia \u00e9s una aproximaci\u00f3 terap\u00e8utica per al tractament del c\u00e0ncer que es basa en l&#8217;\u00fas de virus que s\u00f3n capa\u00e7os de replicar-se i destruir de manera selectiva les c\u00e8l\u00b7lules tumorals. Aquest nou tipus d&#8217;agents anticancer\u00edgens presenta un mecanisme d&#8217;acci\u00f3 \u00fanic en relaci\u00f3 amb els tractaments antitumorals habituals, ja que s\u00f3n capa\u00e7os d&#8217;autoamplificar i propagar l&#8217;efecte oncol\u00edtic.<\/p>\n<p>Actualment VCN Biosciences posseeix en exclusiva dues llic\u00e8ncies de patent de tecnologies independents desenvolupades pel grup de Viroter\u00e0pia de l\u2019ICO-IDIBELL que confereixen una major pot\u00e8ncia antitumoral als adenovirus oncol\u00edtics.<\/p>\n<p>Una d&#8217;elles, la tecnologia hialuronidasa, est\u00e0 integrada en el candidat cl\u00ednic m\u00e9s avan\u00e7at de VCN Biosciences, el virus VCN-01, per al tractament del c\u00e0ncer de p\u00e0ncrees. No obstant aix\u00f2, el disseny i desenvolupament d&#8217;altres candidats v\u00edrics constitueixen tamb\u00e9 alternatives prometedores per al tractament d&#8217;altres tumors refractaris.<\/p>\n<p>VCN-01 \u00e9s un adenovirus que es replica selectivament en c\u00e8l\u00b7lules tumorals i que expressa l&#8217;enzim hialuronidasa humana, enzim que actua degradant l&#8217;\u00e0cid hialur\u00f2nic, un component de la matriu que envolta el tumor. Diversos estudis han demostrat que l&#8217;\u00e0cid hialur\u00f2nic crea una densa matriu que augmenta la pressi\u00f3 en el teixit impedint que els f\u00e0rmacs puguin arribar al tumor. Alguns c\u00e0ncers, com el de p\u00e0ncrees, presenten una elevada concentraci\u00f3 d&#8217;\u00e0cid hialur\u00f2nic, que es relaciona amb la capacitat invasiva i la quimioresist\u00e8ncia. La degradaci\u00f3 d&#8217;aquesta matriu permet l\u2019acc\u00e9s del virus als tumors i facilita l\u2019acci\u00f3 de la quimioter\u00e0pia. VCN-01 es troba ara en fase final de desenvolupament precl\u00ednic i es preveu l&#8217;inici de la fase cl\u00ednica el 2013.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019empresa farmac\u00e8utica multinacional Grifols, a trav\u00e9s de la filial Gri-Cel, ha adquirit el 40% del capital de la companyia biotecnol\u00f2gica catalana VCN Biosciences, dedicada a la recerca i el desenvolupament de nous agents per tractar el c\u00e0ncer basats en adenovirus oncol\u00edtics. VCN va ser fundada l\u2019any 2009 per tres investigadors de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":21574,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[493],"tags":[],"class_list":["post-9486","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-innovacio"],"publishpress_future_action":{"enabled":false,"date":"2025-01-22 10:49:12","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=9486"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9486\/revisions"}],"predecessor-version":[{"id":21575,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9486\/revisions\/21575"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21574"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=9486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=9486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=9486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}